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The optimal role for primary care in providing follow-up for men with prostate cancer is uncertain. A systematic review of
international guidelines was undertaken to help identify key elements of existing models of follow-up care to establish a theoretical
basis for evaluating future complex interventions. Many guidelines provide insufficient information to judge the reliability of the
recommendations. Although the PSA test remains the cornerstone of follow-up, the diversity of recommendations on the provision
of follow-up care reflects the current lack of research evidence on which to base firm conclusions. The review highlights the
importance of transparent guideline development procedures and the need for robust primary research to inform future evidence-
based models of follow-up care for men with prostate cancer.
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Incidence rates of prostate cancer are rising in many countries,
including the United Kingdom. It is now the most commonly
diagnosed cancer in men in Europe (Ferlay et al, 2007) and the
second most common male cancer worldwide (http://info.cancer
researchuk.org/cancerstats/types/prostate/incidence/). The num-
bers of men living with a diagnosis of prostate cancer will
continue to increase as the population ages, and cancer is detected
earlier with the more widespread use of prostate-specific antigen
(PSA) testing.
Management options for localised and locally advanced prostate
cancer include curative treatment, active surveillance and watchful
waiting. The main curative treatments are radical prostatectomy,
external beam radiotherapy (EBRT) and permanent (low-dose)
brachytherapy. Hormone therapy (surgical or medical) may also
be given as neoadjuvant, adjuvant or a stand-alone treatment for
non-metastatic disease. Active surveillance is an option for men
with low- or intermediate-risk localised disease that involves close
monitoring to target curative treatment to those who would benefit
most. Watchful waiting is a way to manage men who are unsuitable
for curative treatment that involves relatively lax monitoring and
palliative treatment when symptoms develop (NICE, 2008).
Metastatic disease is treated palliatively with hormone therapy.
Monitoring and post-treatment follow-up strategies aim to detect
disease progression or recurrence, and manage long-term compli-
cations and treatment-related morbidity.
Traditionally, follow-up care has been hospital based and
provided by clinical specialists in urology and oncology outpatient
clinics. In practice, follow-up is provided in both primary and
secondary care, and is not always well coordinated (Campbell et al,
2002; Neal, 2008) – this is despite widespread calls for better
integrated care (Grunfeld, 2006; Oeffinger and McCabe, 2006;
Department of Health, 2007; Nord et al, 2007). Further, there is
evidence that prostate cancer patients are more likely to have a
worse experience of care, including after care, than those with
other cancers (Department of Health, 2005).
Various alternative models of cancer follow-up care have
emerged, including nurse specialist and primary-care-led follow-
up, and ‘shared care’ approaches. Only specialist nurse-led
prostate cancer follow-up has been evaluated in randomised trials,
which found it to be a safe alternative to consultant-led follow-up
(Helgesen et al, 2000; Faithfull et al, 2001).
In the context of current widespread interest in greater
involvement of primary care in cancer follow-up (Pascoe et al,
2004), we reviewed existing guidelines on follow-up for prostate
cancer as part of a larger study to determine the optimal
role for primary care. It is timely to review international guidelines
to help (1) identify key elements of existing models of care
and (2) establish a theoretical basis for evaluating future complex
interventions.
MATERIALS AND METHODS
Search and selection
One reviewer performed the search and selection and a
second reviewer verified the decisions on inclusion. Relevant
guidelines were identified using the internet search engine
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sSUMSearch, University of Texas, San Antonio, TX, USA (Hasse
et al, 2007), followed by electronic searching of the individual
websites of guideline collections (including clearinghouses and
specialist libraries), guideline development agencies and profes-
sional societies, and finally the bibliographic databases MEDLINE,
Bethesda, MD, USA and EMBASE (Elsevier, Amsterdam, The
Netherlands). The searches were conducted from September to
December 2007 with no language restriction. The sources searched
are listed in Supplementary Table 1. References in the guidelines
identified and personal contacts were consulted to identify
additional guidelines. The pre-defined inclusion criteria were (1)
the guideline was developed by a professional society or a national,
regional, state or provincial government agency, (2) the guideline
originated in the United Kingdom, Western Europe, Australia,
Canada or the United States, (3) the guideline contained
recommendations on post-treatment follow-up, active surveillance
or watchful waiting, (4) the target group was primary or secondary
health-care providers and (5) the date of issue was from 1990
onwards. Selection was thereby limited to current non-commercial
guidelines and countries where the incidence of prostate cancer
has risen over the past two decades and treatment options are
similar.
Where necessary, the body that issued a potentially eligible
guideline was contacted to obtain the full report. The most recent
available version of updated guidelines was used. Additional
reports and supporting material (such as journal articles and web
pages) describing the guideline content, methods, development
process or dissemination strategy, and tools for implementation
were assembled for each included guideline.
Data extraction
One reviewer extracted data using a pro-forma that was checked by
a second reviewer if the guideline was published in English. Data
extraction from guidelines not published in English was based on
translations. Data were extracted for the recommendations on
follow-up (including strategies for active surveillance and watchful
waiting as well as post-treatment follow-up), sources of evidence,
criteria used to grade the quality of the evidence and strength of
the recommendations, and the composition of the guideline
development group.
Quality assessment
The Appraisal of Guidelines Research and Evaluation instrument
was used to assess the quality of the included guidelines
(www.agreecollaboration.org). It has 23 items in six domains:
scope and purpose, stakeholder involvement, rigour of develop-
ment, clarity and presentation, applicability and editorial inde-
pendence. Assessing a guideline involves assigning each item a
score of 1 (low) to 4 (high) and calculating a composite score for
each domain. Domain scores are not aggregated. Two reviewers
independently assessed the guidelines published in English.
Assessment of foreign language guidelines was based on transla-
tions, supporting materials available in English and direct
appraisal by native speakers to obtain, as far as possible, two
independent appraisals.
RESULTS
Included guidelines
Forty-one potentially eligible guidelines were identified. Eighteen
met the inclusion criteria – these are described in Table 1 and are
marked with an asterisk in the reference list. One was still in
preparation. The 22 excluded guidelines are listed in Supplemen-
tary Table 2. The included guidelines were published between 1999
and 2008: 11 originated in Europe (three in the United Kingdom),
three in the United States and four in Canada; 11 were produced by
professional societies and seven by government agencies; and 13
were published in English, two in French and one each in Dutch,
Finnish and Swedish. The scope of most of the guidelines is
prostate cancer management (COIN, 1999; BCCA, 2001; ESMO,
2006; CCNS, 2006; ACB, 2007; CBO, 2007; EAU, 2007; FCCG, 2007;
NCCN, 2007; SBHW, 2007; NICE, 2008); one is specific to follow-up
(AFU, 2005); one is restricted to management of non-metastatic
disease (SOR, 2006); and two are specific to permanent
brachytherapy for localised disease (ESTRO, 2000; ACR, 2005).
One guideline (OMHLTC, 2002) and one best practice policy
statement (AUA, 2000) on PSA, and a guidance document on
urological cancer (including prostate cancer) services (NICE, 2002)
were also included.
Guideline quality
Of the 18 guidelines reviewed, only the recent UK (NICE, 2008),
Dutch (CBO, 2007) and Finnish (FCCG, 2007) guidelines, and the
UK urological cancer services guidance (NICE, 2002), are of high
overall quality according to the AGREE Collaboration’s rating
scheme, indicating that they could be considered for use in
practice without provisos or alterations. The quality of the other 14
guidelines was either moderate (COIN, 1999; AUA, 2000;
OMHLTC, 2002; ACR, 2005; CCNS, 2006; ESMO, 2006; SOR,
2006; SBHW, 2007) or low (ESTRO, 2000; BCCA, 2001; AFU, 2005;
ACB, 2007; EAU, 2007; NCCN, 2007). The Collaboration considers
low-quality guidelines to be more likely to have serious short-
comings and, therefore, not recommended for use in practice. The
domain scores for each guideline are shown in Supplementary
Table 3.
Most (14 out of 18) guidelines failed to describe their scope
and purpose adequately, omitting details of the patient population
to whom the guideline applied, the expected health benefits
and the clinical questions they addressed. Six appeared to have
been developed exclusively by clinical specialists (ESTRO, 2000;
NICE, 2002; AFU, 2005; ESMO, 2006; SOR, 2006; EAU, 2007) and
nine by multidisciplinary groups that also included other
professionals from primary care (a GP or a specialist in family
practice), nursing, psychology and social care (COIN, 1999; AUA,
2000; OMHLTC, 2002; CCNS, 2006; CBO, 2007; FCCG, 2007; NCCN,
2007; SBHW, 2007; NICE, 2008); three provided no information on
the composition of the group (BCCA, 2001; ACR, 2005; ACB, 2007).
Five guidelines involved patients, or their representatives or carers
in the guideline development group, focus groups or in reviewing
draft recommendations (COIN, 1999; NICE, 2002; OMHLTC, 2002;
CBO, 2007; NICE, 2008); 13 gave no indication of having
incorporated patients’ views or preferences. None of the guidelines
were piloted in clinical practice before publication.
A third of the guidelines reported the sources searched
to identify the supporting evidence (COIN, 1999; NICE, 2002;
SOR, 2006; ACB, 2007; CBO, 2007; NICE, 2008). The quality
of the evidence and the strength of the recommendations
were graded using a wide variety of schemes. Most of the
guidelines mentioned consensus in formulating the recommenda-
tions, yet none of them reported formal consensus procedures
or fully described the methods used to reach final decisions or
resolve disagreements. Only six provided clear and explicit links
between the supporting evidence – or its absence – and the
recommendations (AUA, 2000; SOR, 2006; CBO, 2007; FCCG, 2007;
SBHW, 2007; NICE, 2008). Seven appeared not to have
undergone external review before publication (ESTRO, 2000;
BCCA, 2001; OMHLTC, 2002; ACB, 2007; EAU, 2007; NCCN,
2007; SBHW, 2007).
Ten of the guidelines had tools for application, as far as we could
determine. In most cases, it was a single tool, such as a summary
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notable exception, published together with a short version, quick
reference guide and a patient information booklet (NICE, 2008).
The guidelines largely did not consider potential organisational
barriers or the cost implications of applying the recommendations,
or present review criteria for monitoring and audit. A conflict of
interest statement of the guideline group members was missing
from 11 of the 18 guidelines reviewed, and only one stated
explicitly that the views and interests of the funding body did not
influence the recommendations (CCNS, 2006).
RECOMMENDATIONS ON FOLLOW-UP
Service organisation
Most of the included guidelines did not address service organisa-
tion. The latest UK guidelines on prostate cancer (NICE, 2008)
refer to the urological cancer services guidance (NICE, 2002) as the
core model for service delivery, which stresses the importance of
multidisciplinary team management. In all, nine of the guidelines
mentioned the follow-up provider (who) or the setting (where).
The UK guidelines show a shift over time from recommending that
follow-up after treatment with curative intent takes place in a
specialist unit (COIN, 1999) to offering appropriate patients
follow-up outside hospital either by a specialist nurse or in
primary care (NICE, 2002; NICE, 2008). Recent Dutch guidelines
similarly recommend that a specialist nurse or GP can monitor
PSA once it is stable (CBO, 2007), but do not require patients to be
stable for 2 years before being given this option as stipulated in the
UK guidelines (NICE, 2008). Contemporary Swedish and Finnish
guidelines have divergent views: the former omitted the GP in
recommending follow-up by a urologist, oncologist or specialist
nurse, whereas in Finland, only the first post-treatment visit (after
prostatectomy, EBRT or brachytherapy) takes place in secondary
care with all subsequent follow-up in primary care (FCCG, 2007;
SBHW, 2007). Recent guidelines issued in North America continue
to recommend that patients are followed up by specialist clinicians
after radical treatments (ACR, 2005; CCNS, 2008), although it was
one Canadian guideline groups’ policy to refer patients back to the
community ‘as far as practicable’ (BCCA, 2001).
Swedish guidelines specified that the urologist does active
surveillance, whereas a specialist nurse or a GP can do watchful
waiting (SBHW, 2007). In UK guidelines, watchful waiting should
normally be provided in primary care, and primary care services
have responsibility for the day-to-day management of men with
metastatic disease (NICE, 2008). Similarly, according to Finnish
guidelines, men undergoing hormone treatment receive all follow-
up in primary care (FCCG, 2007).
Use of tests and examinations
Prostate-specific antigen testing: International guidelines agree
on the fundamental role of PSA testing in prostate cancer follow-
up, but recommendations on the frequency of tests and the
duration of follow-up are highly inconsistent (Table 2). The
recommended interval between PSA tests in the first year following
prostatectomy or radical radiotherapy varies between 3 and 12
months. There is marked variation in the recommended frequency
of routine testing relative to duration beyond the first year,
irrespective of the type of treatment. The guidelines reflect the lack
Table 1 Included guidelines
Guideline Title Source Quality
a
NICE (2008) Prostate cancer: diagnosis and treatment National Institute for Health and Clinical Excellence High
EAU (2007) Guidelines on prostate cancer European Association of Urology Low
CBO (2007) Guideline on prostate cancer: diagnosis and
treatment [Dutch]
Dutch Institute for Healthcare Improvement (CBO) High
NCCN (2007) Prostate cancer: Clinical Practice Guidelines in
Oncology
The National Comprehensive Cancer Network Low
ACB (2007) Clinical Guidelines: Prostate cancer Alberta Cancer Board Low
FCCG (2007) Prostate cancer: Current Care Guidelines [Finnish] Finnish Medical Society Duodecim High
SBHW (2007) National guideline for prostate cancer management
[Swedish]
Swedish National Board of Health and Welfare Moderate
ESMO (2006) Prostate cancer: clinical recommendations for
diagnosis, treatment and follow-up
European Society for Medical Oncology Low
SOR (2006) Standards, Options and Recommendations for the
management of non-metastatic prostate cancer
[French]
French Federation of Comprehensive Cancer
Centres and French Urological Association
Moderate
CCNS (2006) Guidelines for the management of prostate cancer Cancer Care Nova Scotia Moderate
AFU (2005) Follow-up of prostate cancer [French] French Urological Association Low
ACR (2005) Practice guideline for transperineal permanent
brachytherapy of prostate cancer
American College of Radiology Moderate
OMHLTC (2002) PSA Clinical Guidelines Ontario Ministry of Health and Long-Term Care Moderate
NICE (2002) Improving Outcomes in Urological Cancers National Institute for Health and Clinical Excellence High
BCCA (2001) Cancer Management Guidelines: Prostate British Colombia Cancer Agency Low
ESTRO (2000) Recommendations on permanent seed
implantation for localised prostate cancer
European Society for Therapeutic Radiology and
Oncology
Low
AUA (2000) Prostate-specific antigen (PSA) best practice policy American Urological Association Moderate
COIN (1999) Guidelines on the management of prostate cancer Royal College of Radiology, British Association of
Urological Surgeons
Moderate
Abbreviations: ACB¼Alberta Cancer Board; ACR¼American College of Radiology; AFU¼French Urological Association; AUA¼American Urological Association;
BCCA¼British Colombia Cancer Agency; CBO¼Dutch Institute for Healthcare Improvement; CCNS¼Cancer Care Nova Scotia; COIN¼Royal College of Radiology, British
Association of Urological Surgeons; EAU¼European Association of Urology; ESMO¼European Society for Medical Oncology; ESTRO¼European Society for Therapeutic
Radiology and Oncology; FCCG¼Finnish Current Care Guidelines; NICE¼National Institute for Health and Clinical Excellence; NCCN¼National Comprehensive Cancer
Network; OHMLTC¼Ontario Ministry of Health and Long-Term Care; SBHW¼Swedish National Board of Health and Welfare; SOR¼Standards, Options and
Recommendations.
aQuality was assessed using the Appraisal of Guidelines Research and Evaluation instrument (www.agreecollaboration.org).
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Guideline
Treatment with
curative intent Prostatectomy
External beam
radiotherapy Brachytherapy
Active
surveillance
Watchful
waiting
Advanced and
metastatic disease
NICE (2008) 6 weeks post-
treatment, at least
every 6 months for
the first 2 years,
then at least
annually
Every 3 months in
the first 2 years,
then 6 monthly
At least once a
year
EAU At 3, 6 and 12
months, then every
6 months until 3
years, then annually
3 and 6 months after
initiating treatment,
then every 3–6
months for M1 disease
and good treatment
response CBO At 6 weeks, 3, 6, 9
and 12 months,
then every 6–12
months for 5–10
years
FCCG 6–12 months after
surgery, then every
6 months for 5
years, then every
12 months
At 3 and 12
months after
treatment, then
every 6–12
months for up to 5
years, then annually
At 3 months after
treatment, then
every 6–12
months for up to 5
years, then annually
Every 3–6 months for
5 years, then every 12
months for men on
hormone therapy
SBHW Every 6 months for
2–5 years
Every 3–6 months Every 6–12
months
Every 6–12 months for
patients without known
metastases; every 3–6
months for patients
with metastases; at
least every 3 months
for patients with clinical
progression
NCCN Every 6–12
months for 5 years,
then annually
Every 6 months if
life expectancy
X10 years, every
6–12 months if
o10 years
Every 3–6 months
after initial therapy for
N1 or M1 disease
ACB 4–8 weeks after
surgery, then every
6 months for 2
years, then annually
Every 6 months for
2 years, then
annually
(intermediate risk)
Every 6 months for
2 years, then
annually
(intermediate risk)
As a further
management
option following
radical
prostatectomy:
PSA every 3–4
months
Every 6 months for
advanced disease if it
will affect management
Low risk may have
PSA only annually
PSA should not be
done routinely for
metastatic disease, only
when it will affect
management ESMO PSA should be
monitored
SOR Between 1 and 3
months, then every
3 months in the
first year (less if o
limit of detection)
and every 6 months
for the next 7 years
Every 6 months for
an indefinite period
At regular intervals
CCNS Every 3–12
months in years
1–3 and every 6–
12 months from
year 3 onwards
Every 3–4 months
in years 1–5, then
every 3–6 months
beyond 5 years
Every 6 months
AFU Within 3 months,
then at 6 months,
then, every 6
months for 3 years,
then annually
Every 6 months for
3 years, then
annually
Every 6 months for
10 years is
customary practice
Every 3–6 months Every 6 months
for 4 years,
then annually
At 3 months to
determine nadir
following hormone
therapy
ACR Follow-up at 3–6-
month intervals for
1–2 years, then
periodically, may
include PSA
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that do recommend regular testing differ in how often and for how
long. Guidelines on active surveillance recommend a PSA test
every 3–6 months, some increase the interval to 6 months only
after the first 2 years (BCCA, 2001; NICE, 2008) or simply advise
regular testing (AUA, 2000; NICE, 2002).
UK guidelines advise that men in watchful waiting should have
at least one PSA test a year (NICE, 2008) in contrast to the specific
(but different) test schedules in Swedish and French guidelines
(AFU, 2005; SBHW, 2007). Overall, six guidelines contain similar
recommendations on PSA test frequency after the initiation of
hormone therapy, but three note that follow-up may need to be
tailored to the needs of the patient depending on the type of
hormone treatment, symptoms, clinical condition, age and
prognosis (CCNS, 2006; ACB, 2007; EAU, 2007). Swedish guide-
lines recommend more frequent PSA tests for patients with
metastases than for those without known metastases (SBHW, 2007)
in contrast to one Canadian guideline that recommends routine
PSA testing for advanced disease but not for metastatic disease
(ACB, 2007).
There is also a high degree of variability between guidelines on
what defines biochemical failure, that is, the change in PSA that
should prompt further investigation (Supplementary Table 4).
Most guidelines adopt expert panel standard definitions for
biochemical failure following EBRT, but show a clear lack of
consensus in regard to brachytherapy and prostatectomy – and a
dearth of advice on active surveillance, watchful waiting and
advanced disease.
Digital rectal examination and other tests: Guidelines on routine
digital rectal examination (DRE) following treatment with curative
intent fall into three categories: either it is not recommended (as
long as PSA is stable) (CBO, 2007; NICE, 2008) or it is
recommended supplementary to PSA testing, either with each
PSA test (BCCA, 2001; OMHLTC, 2002; SOR, 2006; EAU, 2007) or
less frequently (AFU, 2005; CCNS, 2006; ACB, 2007; NCCN, 2007)
(Table 3). The type of curative treatment, prostatectomy or
radiotherapy, does not explain these conflicting recommendations.
It is also evident that there is no consensus on the use of DRE
following brachytherapy. Six guidelines recommend DRE in the
course of active surveillance (AUA, 2000; NICE, 2002; OMHLTC,
2002; CCNS, 2006; NCCN, 2007; SBHW, 2007) in contrast to the
NICE guidelines’ recommendation against it as long as PSA
remains at baseline levels (NICE, 2008). The NICE guidelines also
recommend against routine DRE for men undergoing watchful
waiting (NICE, 2008). Guidelines that advised on DRE during
routine follow-up after initiation of hormone therapy recommend
that it should be performed with each PSA test (OMHLTC, 2002;
EAU, 2007; NCCN, 2007).
Biopsy, and imaging and biochemical tests other than
PSA feature irregularly in follow-up recommendations.
Four European guidelines agree that routine biopsy and imaging
is unnecessary following treatment with curative intent if
patients are asymptomatic and PSA is low and stable (AFU,
2005; SOR, 2006; CBO, 2007; EAU, 2007). Active surveillance
should include at least one re-biopsy according to UK guidelines
that do not specify the timing (NICE, 2008); other guidelines
recommend it within 18 months, then periodically (CCNS, 2006;
NCCN, 2007) or every 3 years (BCCA, 2001). Dutch and French
guidelines (AFU, 2005; CBO, 2007) do not recommend routine
biochemistry, such as creatinine, transaminases and testosterone,
for follow-up of asymptomatic patients following treatment with
curative intent, but Swedish guidelines do include creatinine and
haemoglobin in routine follow-up after curative radiotherapy as
well as during active surveillance and watchful waiting (SBHW,
2007). Regular monitoring of creatinine, haemoglobin and liver
function tests (alkaline phosphatase or alanine aminotransferase)
is recommended in European Association of Urology guidelines on
metastatic disease and in concurrent Swedish guidelines on follow-
up after hormone therapy (EAU, 2007; SBHW, 2007).
Complications and adverse effects
Specific recommendations on the evaluation of complications and
treatment-related adverse effects appear infrequently in guidelines:
Table 2 (Continued)
Guideline
Treatment with
curative intent Prostatectomy
External beam
radiotherapy Brachytherapy
Active
surveillance
Watchful
waiting
Advanced and
metastatic disease
OMHLTC At 3–12-month
intervals
At 3–12-month
intervals
Role not yet
established
At 3–6-month
intervals
At 3–6-month
intervals for men
undergoing hormone
therapy
NICE (2002) Regular
BCCA Every 3 months in
the first year, then
every 6 months
Every 6 months for
3 years, then
annually
Every 3 months for
2 years, then 6
monthly
ESTRO Follow-up every 3
months for the first
year, then every 6
months to 5 years,
then annually,
should include PSA
AUA Periodic Periodic, no more
than every 3–6
months
Consider regular
tests
COIN It is sensible to monitor
PSA every 3 months
when hormone
treatment for
metastatic disease is
deferred
Abbreviations: DRE¼digital rectal examination; PSA¼prostate-specific antigen.
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sthose for Nova Scotia singularly recommend establishing a specific
schedule of follow-up visits after radical treatment to discuss and
manage urinary incontinence, erectile dysfunction and sexual
health, and suggest routine screening for men considered to be at
high risk for psychosocial distress throughout the course of the
disease (CCNS, 2006). UK guidelines recommend that men and
their partners are given the opportunity to discuss psychosexual
problems (NICE, 2008) and that counselling on sexual problems
and incontinence is made available for as long as it is needed
(NICE, 2002).
DISCUSSION
This study is the first to review prostate cancer guidelines
systematically and to summarise international guideline recom-
mendations on follow-up. Although monitoring PSA remains the
cornerstone of follow-up for men with prostate cancer, the
diversity of guideline recommendations on the frequency and
duration of PSA testing, and components of follow-up other than
PSA testing, reflects the current lack of research evidence on which
to base firm conclusions. The guidelines provide only broad
Table 3 Guidelines follow-up recommendations on DRE
Guideline
Treatment with
curative intent Prostatectomy
External beam
radiotherapy Brachytherapy
Active
surveillance Watchful waiting
Advanced and
metastatic
disease
NICE (2008) Not recommended
as routine while PSA
remains at baseline
levels
Not recommended
while PSA remains at
baseline levels
Not recommended
while PSA remains at
baseline levels
-
EAU At 3, 6 and 12
months, then every 6
months until 3 years,
then annually
At 3 and 6 months,
then every 6 months
for M0 and good
treatment response,
every 3–6 months
for M1 and good
treatment response
CBO Not recommended
as routine if PSA is
decreasing or low and
stable
SBHW Every 3–6 months
NCCN Annually Every 6 months if life
expectancy 10 years,
every 6–12 months if
o10 years
Every 3–6 months
after initial therapy for
N1 or M1
ACB Annually Annually
SOR Optional for patients
with total serum PSA
o limit of detection
Every 6 months for an
indefinite period
At regular intervals
CCNS Every 6–24 months
in years 1–5, then
every 1–3 years
Every 6 months
AFU Recommended if
PSA detectable or
indicates a higher
grade tumour or risk
of local relapse is
important
Annually Annually for 10 years
is customary practice
ACR Follow-up at 3–6
month intervals for
1–2 years, then
periodically, may
include DRE
OMHLTC At 3–12-month
intervals
At 3–12-month
intervals
At 3–6-month
intervals
At 3–6-month
intervals for men
undergoing hormone
therapy
NICE (2002) Regular
BCCA Every 3 months in the
first year, then every
6 months
Every 6 months for 2
years, then 6 monthly
ESTRO Follow-up every 3
months for the first
year, then every 6
months to 5 years,
then annually, should
include DRE
AUA Consider regular tests
Abbreviations: DRE¼digital rectal examination.
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up care, particularly in terms of the setting and the composition of
the health-care team.
In conducting this review, we had a specific interest in the
role of primary care in prostate cancer follow-up. The included
guidelines illustrate the disagreement that persists on the extent
to which primary care should be involved. The recommendations
in recent guidelines that highlight primary-care-based follow-up
would require considerable effort and investment to imple-
ment – in terms of education, protocols and strategies to
change established practice (Grol et al, 1998; Foy et al, 2002).
Furthermore, cancer follow-up in the community requires a
close cooperation between primary and secondary care
services. However, there has been little research on the best way
to manage processes of care involving related actions and
decisions by different care providers and, as this review
shows, practice guidelines seldom address implementation
(Grol et al, 2003). Guidelines recommending follow-up in the
community give only general guidance, such as agreeing
shared care protocols, maintaining close contact between all
professionals involved and having mechanisms in place to allow
primary care providers access to specialist services. With the
current focus on integrated models of chronic care, there
are, again, limitations on the usefulness of existing guidelines
(Barr et al, 2003).
The paucity of high-quality studies in the literature on prostate
cancer follow-up has important implications, particularly for
primary care, because recommendations based on explicit and
non-conflicting scientific evidence are adhered to more in general
practice (Grol et al, 1998). It underlines the importance of
strengthening the evidence base on prostate cancer follow-up and
keeping guidelines up to date as new evidence emerges.
Our review has some limitations to consider. Identifying
guidelines largely through electronic sources may have introduced
bias towards English language guidelines and guidelines produced
by larger, well-established organisations. Conversely, searching
multiple sources, using foreign language search terms and pre-
defining inclusion criteria on guideline developers, should have
reduced the risk of language bias and failing to identify guidelines
from eligible sources. We acknowledge that all relevant informa-
tion may not have been included in the translations of foreign
language guidelines and that quality assessment based on
translations may not be entirely accurate. Nevertheless, our
findings are consistent with earlier studies that have noted
conflicting guideline recommendations on prostate cancer diag-
nosis and treatment (Meyer et al, 2006) and shortcomings in the
methods used by leading urological associations to develop
guidelines for prostate cancer (Dahm et al, 2007). The guidelines
we reviewed were produced in developed countries with similar
prostate cancer incidence trends and management options,
consequently our findings may not be generalisable to other
settings.
The methodological quality of the guidelines included in our
review was heterogeneous and in most cases moderate to poor. We
used the AGREE instrument as the indicator of guideline quality
because it is validated and considered to be the international
standard in guideline assessment (Vlayen et al, 2005). The criteria
mainly address the methods of guideline development and the
quality of reporting. The high-quality guidelines in this review
were generally well reported and achieved high scores on almost all
domains. However, inadequate and incomplete reporting cannot
be ruled out as a reason for lower quality scores (Fervers et al,
2005). Guidelines of similar methodological quality still differ in
their recommendations on prostate cancer follow-up, indicating
that important influences on guideline development are not always
explicit. Furthermore, in common with other critical appraisal
tools for guidelines, the AGREE instrument does not assess the
clinical content of the recommendations or the quality of the
supporting evidence. Good methodological quality does not
necessarily indicate good-quality recommendations (Burgers,
2006).
Most of the guidelines in our review combined an evidence-
based approach with informal consensus – reflecting the status of
the international literature in this field (Martin et al, 2006; Warren
and McFarlane, 2007). When recommendations are formulated by
consensus comprehensive stakeholder involvement, transparent
consensus procedures and editorial independence are especially
important for guideline credibility (Fervers et al, 2005). We found
that these important elements are often not evident in
prostate cancer guidelines. The balance between individual and
speciality biases in guidelines development groups could, in
part, account for different recommendations on who provides
follow-up and in what setting. For example, guidelines recom-
mending that clinical specialists provide follow-up were
more likely to have been developed exclusively by representatives
of that group. Those that recommend involvement of nurse
specialists and primary care were largely developed by multi-
disciplinary groups that included a range of care providers and
sought the views of service users. Research in other clinical areas
has shown that speciality groups favour procedures in which they
have a vested interest and even when presented with the same
evidence will reach different conclusions than wider multi-
disciplinary groups (Murphy et al, 1998; Shekelle et al, 1999;
Fretheim et al, 2006). Members of guideline development groups
may also more readily endorse models of care that have already
been implemented in their locality. When the consensus procedure
is ill defined, it is difficult to ascertain which aspects might have
influenced the outcome or how reliably expert opinion and
stakeholders’ preferences were incorporated (Grol et al, 2003;
Raine et al, 2005).
Reviews of international guidelines such as ours often find that
recommendations are shaped or constrained by the structure and
organisation of their country’s health-care systems, even when the
evidence is incontrovertible (Eisinger et al, 1999; Burgers et al,
2002; Philip et al, 2003). In the United Kingdom, for example,
cancer plans (NHS, 2000; Department of Health, 2007) have
emphasised patient preference on the delivery of cancer care and
alternative models of health-care delivery, which bring care closer
to the patient – these elements are reflected in the latest UK
guidelines on prostate cancer (NICE, 2008).
Ultimately, the usefulness of a guideline needs to take
account of the impact on patient outcomes of applying the
recommendations in local settings. Systematic appraisal
can aid informed judgment on guideline quality: guideline
recommendations can only be rigorously tested by incorporating
them in the development of interventions for evaluation in
randomised trials.
CONCLUSIONS
This review shows the current status of international guidelines in
prostate cancer follow-up. The variability in recommendations to
some extent reflects the lack of definitive evidence from research in
this field. Choices over management in prostate cancer, including
follow-up, can only be informed to a limited extent by evidence
from high-quality trials.
The review illustrates the importance of rigorous and transpar-
ent guideline development processes when research evidence is
limited, without which it is difficult to assess factors such as
independence and impartiality. It also highlights the need for
robust primary research to improve the evidence base for prostate
cancer follow-up – particularly research to inform best practice
models of care. Only then can the many new models of
care emerging internationally be shaped in a rational, evidence-
based way.
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